Author

admin

Browsing

Sen. Cory Booker, D-N.J., spoke out against President Donald Trump and Elon Musk on the Senate floor throughout the night after beginning his marathon speech at 7 p.m. Monday.

More than 24 hours later, at 7:20 p.m. on Tuesday, Booker had broken the record for the longest Senate floor speech, before finally calling it quits at 8:05 p.m.

In the lead up to breaking the speech record formerly held by former Sen. Strom Thurmond, D/R-S.C., nearly 70 years ago, Booker yielded to Sen. Chuck Schumer, D-N.Y., so he could ask the New Jersey Senator a question.

‘Do you know you have just broken the record?’ Schumer asked. ‘Do you know how proud this caucus is of you? Do you know how proud America is of you?’

Everyone in the chamber, besides the press, gave Booker a standing ovation, including those in the gallery and senate pages.

Sen. Tina Smith, D-Minn., was seen wiping a tear from her face, while Sen. Cynthia Lummis, R-Wyo., was also seen standing and applauding.

Forty-five minutes later, Booker had concluded his speech.

Booker received some support from other Senate Democrats, whom he allowed to speak at times during his hours-long show of opposition against the Trump administration.

Booker said toward the beginning of his speech that Trump, in 71 days, ‘has inflicted so much harm on Americans’ safety, financial stability, the core foundations of our democracy, and even our aspirations as a people for, from our highest offices, a sense of common decency.’

Sen. Cory Booker says he will not be taking up Musk on Cybertruck offer

The senator claimed that the Trump administration and congressional Republicans are targeting Medicaid and Medicare programs to fund tax cuts for billionaires and corporations.

He spent some of his time reading messages from people who wrote about various topics, including concerns about Medicare, Medicaid, and Social Security.

Trump has previously indicated that he will not ‘touch’ Americans’ Social Security, Medicare, or Medicaid benefits, but wants to weed out fraud.

Sen. Chris Murphy, D-Conn., who said he planned to join Booker ‘for the entirety of his speech,’ noted that he was ‘returning the favor’ as Booker joined him when he ‘launched a filibuster to demand action on gun violence nine years ago.’

Cory Booker blasts Trump during marathon speech

Murphy was among the Democrats who provided Booker with some relief by speaking at times to punctuate the marathon session.

In the social media video, Murphy described his colleague’s effort as ‘extraordinary.’

Booker said in a video before he began his demonstration that he plans to continue speaking as long as he is ‘physically able.’

After pontificating for 25 hours, Booker took a brief moment in his office before facing a group of reporters.

He told reporters that despite fasting for days and drinking water, his muscles started to cramp up during the marathon speech. He even said he was tired and sore.

‘There’s just a lot of tactics I was using to make sure that I could stand for that long,’ Booker said.

But when asked if he felt his speech moved the needle in any way and whether Democrats should employ the same tactic going forward to protest the Trump agenda, Booker said he had not had much time to digest and think about it.

‘There’s a lot of people out there asking Democrats to do more and to take risks and do things differently,’ he said. ‘This seemed like the right thing to do, and from what my staff is telling me…a lot of people watched. And so, we’ll see what it is. I just think a lot of us have to do a lot more, including myself.’

Booker said he was aware of Strom Thurmond’s record speech, but always felt it was a strange shadow to hang over in the Senate.

‘All the issues that have come up on noble causes that people have done, or the things it took to try to stop, I just found it strange that he had the record,’ he said. ‘I didn’t want to set expectations. [The] mission was really to elevate the voices of Americans to tell some of their really painful stories, very emotional stories, and to let them let go and let God do the rest.’


This post appeared first on FOX NEWS

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is still trading at three-year highs, despite current market volatility, in response to breakthrough innovations and increased deals involving biotech stocks listed on the NASDAQ.

After dropping to a low of 3,637.05 in October 2023, the index climbed to a nearly three year peak of 4,954.813 on September 19, 2024. While the index had pulled back to 4,243.7 as of March 31, 2025, further growth could be in store in the future.

According to a Towards Healthcare analyst report, the global biotech market is expected to grow at a compound annual growth rate of 12.5 percent from now to 2034, reaching a valuation of US$5.036 trillion.

Driving that growth will be favorable government policies, investment in the sector, increased demand for synthetic biology and a rise in chronic disorders such as cancer, heart disease and hypertension.

The top NASDAQ biotech stocks have seen sizeable share price increases over the past year. For those interested in investing in biotech companies, the best-performing small-cap biotech stocks are outlined below.

Data was gathered on March 31, 2025, using TradingView’s stock screener. Small-cap biotech stocks with market caps between US$50 million and US$500 million at that time were considered for this list.

1. Bright Minds Biosciences (NASDAQ:DRUG)

Company Profile

Year-over-year gain: 2,942.02 percent
Market cap: US$254.99 million
Share price: US$36.20

Bright Minds Biosciences is developing novel treatments for pain and neuropsychiatric disorders such as epilepsy, post-traumatic stress disorder and difficult-to-treat depression.The company’s platform includes serotonin agonists designed to provide powerful therapeutic benefits while minimizing side effects.

Bright Minds is currently in Phase 2 clinical trials for BMB-101, a highly selective 5-HT2C receptor agonist, in adult patients with classic absence epilepsy and developmental epileptic encephalopathy.

Bright Minds’ share price rocketed upward in the fourth quarter of last year, shooting up from US$2.49 to US$38.49 in one day on October 15. The company issued a press release at the time, stating it was ‘unaware of any material changes in the company’s operations’ that would have contributed to such a rally.

The outperformance appears to be related to the October 14 news that Danish pharma company H. Lundbeck was to acquire Longboard Pharma, a company developing a 5-HT2C receptor agonist, for US$60 per share.

A few days later, Bright Minds announced a non-brokered private placement of US$35 million, which sent shares up to US$47.21 on October 18.

That same month, the company shared its collaboration with Firefly Neuroscience (NASDAQ:AIFF) to use Firefly’s Brain Network Analytics technology platform to provide a full analysis of the electroencephalogram data from Bright Minds’ BMB-101 Phase 2 clinical trial. This follows the pair’s previous successful collaboration to analyze data from Bright Minds’ first-in-human Phase 1 study of BMB-101.

In March 2025, Bright Minds expanded its Scientific Advisory Board with the addition of five experts in epilepsy research.

Bright Minds’ share price reached US$55.77, its peak for the past year, on November 6.

2. Monopar Therapeutics (NASDAQ:MNPR)

Company Profile

Year-over-year gain: 924.54 percent
Market cap: US$220.3 million
Share price: US$36.10

Clinical-stage biotech Monopar Therapeutics’ main drug candidate is its late-stage ALXN-1840 for Wilson disease. Its pipeline also includes radiopharma programs such as Phase 1-stage MNPR-101-Zr for imaging advanced cancers, as well as Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers.

Shares in Monopar spiked by more than 600 percent on October 24, 2024, to US$32.66 following its news release detailing its exclusive worldwide licensing agreement with Alexion, AstraZeneca’s (NASDAQ:AZN) Rare Disease unit, for ALXN-1840, a drug candidate for Wilson disease that met its primary endpoints in its Phase 3 clinical trial. Going forward, Monopar will be responsible for all future global development and commercialization activities.

Further positive news flow in December continued to drive the company’s stock value. Early in the month, the company shared that the first patient was dosed with MNPR-101-Lu in its Phase 1a trial for the radiopharmaceutical. A few weeks later, Monopar announced the launch of a US$40 million concurrent public offering and private placement. After having fallen back to the US$22 range, shares in the company climbed to US$30.68 on December 17, 2024.

Positive sentiment in the company and the biotech market would later drive the stock up to its yearly high of US$51.89 on February 10, 2025. Monopar released its Q4 and full-year 2024 results on March 31.

3. Candel Therapeutics (NASDAQ:CADL)

Company Profile

Year-over-year gain: 268.3 percent
Market cap: US$262.39 million
Share price: US$5.64

Candel Therapeutics is a biotech company focused on developing oncology treatments. The company’s pipeline includes two clinical-stage multimodal biological immunotherapy platforms.

Candel’s lead product candidate, CAN-2409, is in a Phase 2 clinical trial in non-small cell lung cancer and borderline resectable pancreatic cancer, as well as Phase 2 and 3 trials for localized, non-metastatic prostate cancer.

The company had a number wins with the US Food and Drug Administration (FDA) in 2024. In February and May, respectively, Candel’s CAN-3110 received regulatory approval for fast-track designation and orphan drug designation for the treatment of recurrent high-grade glioma.

The agency also granted Candel orphan drug designation for CAN-2409 for the treatment of pancreatic cancer in April 2024. Positive interim data for the trial on pancreatic cancer released that month, sent the company’s share price spiking upward. It ultimately climbed to its 2024 high point of US$14.00 on May 15, 2024.

So far in 2025, Candel’s share price has traded as high as US$12.21 on February 20. In its January corporate update, the company shared its goals for the year, including aiming for Q4 for reporting overall survival data in patients with recurrent high-grade glioma from its ongoing phase 1b trial that is evaluating multiple doses of CAN-3110.

4. Tiziana Life Sciences (NASDAQ:TLSA)

Company Profile

Year-over-year gain: 154.76 percent
Market cap: US$119.51 million
Share price: US$1.08

Tiziana Life Sciences is a clinical-stage biopharma which is developing therapies for autoimmune and inflammatory diseases, degenerative diseases, and cancer-related to the liver. Its pipeline of candidates is built on its patent drug delivery technology that provides a possible alternative to intravenous (IV) delivery. Tiziana’s lead candidate is intranasal foralumab, which it says is the only fully human anti-CD3 mAb currently in clinical development.

On May 31, 2024, shares in Tiziana broke above US$1 after a series of positive news flow for the company. This included positive clinical results from its intermediate sized Expanded Access Program for non-active secondary progressive multiple sclerosis patients, which demonstrated multiple improvements in foralumab-treated patients, as well as its submission of an orphan drug designation application to the FDA for intranasal foralumab for the treatment of non-active secondary progressive multiple sclerosis (na-SPMS).

While Tiazana’s share price slid back down below US$1 per share by mid-June 2024, news that the FDA granted fast track designation to Tiziana intranasal foralumab for the treatment of na-SPMS gave it a much needed boost to the upside. By August 12, the stock’s value had risen to US$1.45 per share.

Tiziana Life Sciences shares reached a yearly peak of US$1.69 on March 7, 2025, after the company filed its investigational new drug application to the FDA for a phase 2 clinical trial in amyotrophic lateral sclerosis (ALS), which is supported by the ALS Association.

5. Benitec Biopharma (NASDAQ:BNTC)

Company Profile

Year-over-year gain: 149.71 percent
Market cap: US$331.43 million
Share price: US$13.01

California-based Benitec Biopharma is advancing novel genetic medicines via its proprietary “Silence and Replace” DNA-directed RNA interference platform. The company is currently focused on developing therapeutics for chronic and life-threatening conditions, including oculopharyngeal muscular dystrophy (OPMD).

Its drug candidate BB-301 was granted orphan drug designation by the FDA and the European Medicines Agency. Benitec is well funded to advance its BB-301 clinical development program through the end of 2025.

Benitec’s share price benefited from its first bump of the past year, after the company released its fiscal year Q3 2024 update in mid-May highlighting its achievements over the quarter. This included the closing of a US$40 million private placement. Benitec’s stock value hit US$10.47 per share on May 20, 2024.

Later in the fall, the company reported positive data from two patients with OPMD treated with low-dose BB-301 in phase 1b/2a study, showing the clinical trial is meeting key safety and efficacy endpoints. Shares hit another high of US$11.22 on October 17, 2024.

Benitec’s share price hit US$16.79, its highest yearly value to date, on March 20, 2025, a day after the company released positive interim clinical results for three patients with OPMD treated with BB-301 in phase 1b/2a study.

“The sixth and final Subject of Cohort 1 will be treated with BB-301 in the second calendar quarter of this year, and we are highly optimistic about the potential for continued benefit in Subjects enrolled in the ongoing clinical study,” said Jerel A. Banks, Benitec Executive Chairman and CEO.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES.

Cartier Resources Inc. (TSX-V: ECR) (‘ Cartier ‘ or the ‘ Corporation ‘) announces the execution, on March 31, 2025, of an amending agreement (the ‘ Amending Agreement ‘) further to the engagement letter dated March 20, 2025 between Paradigm Capital Inc. (the ‘ Agent ‘) and the Corporation (the ‘ Engagement Letter ‘) with respect to its previously announced ‘best efforts’ private placement offering of securities of Cartier (the ‘ Offering ‘).

The Amending Agreement was concluded to address potential impacts of several tax measures unveiled on March 25, 2025 by the Minister of Finance (Québec) in connection with his 2025-2026 budget (the ‘ 2025 Québec Budget ‘).

The Offering will continue to raise aggregate gross proceeds for the Corporation of up to approximately $7,300,160 (subject to a potential increase thereof for additional gross proceeds of up to $1,095,024 in accordance with the exercise of the Agent’s Option, as further described below).

The Offering remains a combination of: (a) units of the Corporation issued on a charitable flow-through basis that will qualify as ‘flow-through shares’ within the meaning of subsection 66(15) of the Income Tax Act (Canada) (the ‘ Tax Act ‘) and section 359.1 of the Québec Tax Act (the ‘ Premium FT Units ‘) for gross proceeds of approximately $5,000,200; and (b) units of the Corporation (the ‘ Hard Dollar Units ‘) and, together with the Premium FT Units, the ‘ Offered Securities ‘) at $0.13 per Hard Dollar Unit for gross proceeds of $2,299,960. Each Premium FT Unit consists of one common share in the capital of the Corporation (each a ‘ Common Share ‘) and one common share purchase warrant (each a ‘ Premium FT Warrant ‘), with each such Common Share and Premium FT Warrant qualifying as a ‘flow-through share’ within the meaning of subsection 66(15) of the Tax Act and section 359.1 of the Québec Tax Act. Each Hard Dollar Unit consists of one Common Share of the Corporation and one common share purchase warrant (each a ‘ Hard Dollar Warrant ‘), and for certainty, each such Common Share and Hard Dollar Warrant will not qualify as a ‘flow-through share’.

Under the Engagement Letter, the subscription price of the Premium FT Units (the ‘ FT Subscription Price ‘) was set on March 20, 2025 at $0.23 per FT Unit, based on certain tax benefits then available under the Quebec Tax Act and the Tax Act, including, but not limited to, the Québec Capital Gain Exemption and Québec Additional Deductions (each as defined herein).

The 2025 Québec Budget introduced major changes to the flow-through share regime under the Taxation Act (Québec) (the ‘ Québec Tax Act ‘), including the following measures (collectively, the ‘ 2025 Québec Budget Amendments ‘):

(a) abolition of the capital gains exemption in respect of the disposition of certain ‘resource property’ (within the meaning of the Québec Tax Act) (the ‘ Québec Capital Gain Exemption ‘); and
(b) abolition of both (i) the additional 10% deduction under the Québec Tax Act in respect of certain exploration expenses incurred in Québec and (iii) the additional 10% deduction under the Québec Tax Act in respect of certain surface mining exploration expenses incurred in Québec (collectively, the ‘ Québec Additional Deductions ‘).

However, the 2025 Québec Budget provides that the abolition of the Québec Additional Deductions will not apply to flow-through shares issued after March 25, 2025 if they are issued following a public announcement made no later than March 25, 2025 (which is the case of the Offering), provided furthermore that a report of exempt distribution is filed with the Autorité des marchés financiers no later than May 31, 2025 (the ‘ Grandfathering Exception ‘).

Considering the potential impacts of the 2025 Québec Budget Amendments as announced on March 25, 2025, the Corporation, on March 31, 2025, (a) entered into the Amending Agreement; and (b) entered into a subscription and renunciation agreement with PearTree Securities Inc. (‘ PearTree ‘), on behalf of certain disclosed principals (the ‘ Subscription and Renunciation Agreement ‘).

Pursuant to the Subscription and Renunciation Agreement, a mechanism was introduced to allow for the adjustment of the FT Subscription Price to $0.205 or $0.182 from $0.23 (i.e. the price initially agreed upon on March 20, 2025 under the Engagement Letter) depending on whether the Québec Capital Gain Exemption and/or Québec Additional Deductions are determined on the Closing Date (as defined herein) to be available in respect of the Offering, based on any written statements that are issued by the Minister of Finance (Québec) to clarify the scope of the 2025 Québec Budget Amendments and the Grandfathering Exception. Under the Subscription and Renunciation Agreement, corresponding adjustments would also be made to the number of Premium FT Units issued so as to retain approximately the same aggregate gross subscription proceeds.

All of the other material terms of the Offering remain unchanged, including the following:

  • The gross proceeds from the sale of the Premium FT Units will be used by the Corporation to incur eligible ‘Canadian exploration expenses’ that qualify as ‘flow-through mining expenditures’ (as both terms are defined in the Tax Act) (the ‘ Qualifying Expenditures ‘) related to the projects of the Corporation in Québec. The Qualifying Expenditures will be renounced in favour of the subscribers of the Premium FT Units with an effective date no later than December 31, 2025 and in an aggregate amount of not less than the total amount of the gross proceeds raised from the issuance of the Premium FT Units.
  • Each Premium FT Warrant and Hard Dollar Warrant will entitle the holder thereof to acquire one Common Share of the Corporation (each a ‘ Warrant Share ‘) on a non-flow-through basis at an exercise price of $0.18 for a period of 5 years following the Closing Date (as herein defined).
  • The Corporation will grant the Agent an option (the ‘ Agent’s Option ‘), exercisable up to 48 hours prior to the Closing Date (as herein defined), to sell that number of Offered Securities for additional gross proceeds of up to $1,095,024.

The Offering is being made by way of private placement in Canada. The Offered Securities will be subject to a four month and one day hold period under applicable securities laws in Canada. The Offering is expected to close on or about April 14, 2025 (the ‘ Closing Date ‘), subject to the satisfaction or waiver of customary closing conditions, including the conditional listing approval of the TSX-V.

About Cartier Resources Inc.

Cartier Resources Inc., founded in 2006, is an exploration company based in Val-d’Or. The Corporation’s projects are all located in Québec, which consistently ranks among the world’s top mining jurisdictions. Cartier is advancing the development of its flagship Cadillac project, consisting of the Chimo Mine and East Cadillac properties, and its other projects. The Corporation has corporate and institutional support, including Agnico Eagle and Québec investment funds.

This news release does not constitute an offer of securities for sale in the United States. The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold in the United States absent registration in the United States or an applicable exemption from the registration requirements in the United States.

Cautionary Note Regarding Forward-Looking Information

This news release contains ‘forward-looking information’ within the meaning of the applicable Canadian securities legislation that is based on expectations, estimates, projections, and interpretations as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, interpretations, beliefs, plans, projections, objectives, assumptions, future events or performance including in respect of the use of proceeds of the Offering, closing of the Offering and the tax treatment of the flow through shares (often but not always using phrases such as ‘expects’ or ‘does not expect’, ‘is expected’, ‘interpreted’, ‘management’s view’, ‘anticipates’ or ‘does not anticipate’, ‘plans’, ‘budget’, ‘scheduled’, ‘forecasts’, ‘estimates’, ‘believes’ or ‘intends’ or variations of such words and phrases or stating that certain actions, events or results ‘may’ or ‘could’, ‘would’, ‘might’ or ‘will’ be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information and are intended to identify forward-looking information. This forward-looking information is based on reasonable assumptions and estimates of management of the Corporation, at the time it was made, involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Corporation to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Although the forward-looking information contained in this news release is based upon what management believes, or believed at the time, to be reasonable assumptions, the parties cannot assure shareholders and prospective purchasers of securities that actual results will be consistent with such forward-looking information, as there may be other factors that cause results not to be as anticipated, estimated or intended, and neither the Corporation nor any other person assumes responsibility for the accuracy and completeness of any such forward-looking information. The Corporation does not undertake, and assumes no obligation, to update or revise any such forward-looking statements or forward-looking information contained herein to reflect new events or circumstances, except as may be required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

For more information, contact:

Philippe Cloutier, P. Geo.
President and CEO
Phone: 819-856-0512
Email: philippe.cloutier@ressourcescartier.com
www.ressourcescartier.com

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

This post appeared first on investingnews.com

The House Foreign Affairs Committee (HFAC) is demanding that the United Nations not reappoint Special Rapporteur Francesca Albanese. Rep. Brian Mast, R-Fla., who chairs the committee, is leading the charge to oppose Albanese.

In a letter to U.N. Human Rights Council (UNHRC) President Jürg Lauber, the committee accuses Albanese of failing to uphold the council’s code of conduct. They also condemn Albanese for comments she made about Israel in the wake of Hamas’ Oct. 7 attacks.

‘Albanese unapologetically uses her position as a UN Special Rapporteur to purvey and attempt to legitimize antisemitic tropes, while serving as a Hamas apologist,’ the committee wrote in its letter. ‘In her malicious fixation, she has even called for Israel to be removed from the United Nations while likening Israel to apartheid South Africa.’

The committee not only criticized Albanese but also slammed the UNHRC, saying its leaders ‘allowed antisemitism and anti-Americanism to thrive within, with a seeming unwillingness to hold the most egregious violators of human rights to account.’

‘Francesca Albanese is an unabashed anti-Israel activist who has consistently done the bidding of Hamas terrorists responsible for the heinous October 7th attacks. Her appointment is a disgrace to the U.N. It’s time for the U.N. to claw back the integrity and accountability it has surrendered,’ Mast told Fox News Digital.

U.N. Watch Executive Director Hillel Neuer lauded the ‘much needed’ action from Congress. In a statement to Fox News Digital, Neuer said that Albanese’s reappointment would be ‘unlawful’ and called for ‘consequences’ from the U.S. if she visits the country.

‘Francesca Albanese openly supports Hamas, spreads antisemitic tropes, and tramples the U.N.’s own Code of Conduct. Under the U.N.’s own rules, the president of the Human Rights Council is now duty-bound to convey to the plenary this and other substantial objections that have been submitted, and for the delegates to formally consider Albanese’s many violations. And yet every indication is that the 47-member body — with the EU’s complicity — is instead barreling ahead with Albanese’s reappointment,’ Neuer said in a statement to Fox News Digital.

Albanese, who was appointed special rapporteur in 2022, has been condemned by the governments of multiple countries and faced accusations of antisemitism. Her response to French President Emmanuel Macron calling the Oct. 7 attacks ‘the largest antisemitic massacre of our century’ sparked backlash from France, the U.S. and Germany.

The U.S. slammed Albanese for her ‘history of using antisemitic tropes,’ and said her comments were ‘justifying, dismissing [and] denying the antisemitic undertones of Hamas’ October 7 attack are unacceptable [and] antisemitic.’

The French Mission to the U.N. condemned Albanese’s response in a post on X. According to the Anti-Defamation League’s (ADL) translation, the post read: ‘The October 7 massacre is the largest antisemitic massacre of the 21st century. To deny it is wrong. To seem to justify it, by bringing in the name of the United Nations, is a shame.’ This was just a few months after the mission condemned her ‘hate speech and antisemitism.’

Germany retweeted France’s statement and said, ‘To justify the horrific terror attacks of 7/10 & deny their antisemitic nature is appalling. Making such statements in a UN capacity is a disgrace and goes against everything the United Nations stands for.’

The Office of the High Commissioner for Human Rights did not immediately respond to Fox News Digital’s request for comment.


This post appeared first on FOX NEWS

The National Security Council (NSC) has clarified reporting about National Security Advisor Michael Waltz and his staffers using personal Gmail accounts for government communications.

A report published by the Washington Post on Tuesday claimed that one of Waltz’s senior aides used Gmail ‘for highly technical conversations with colleagues at other government agencies involving sensitive military positions and powerful weapons systems relating to an ongoing conflict,’ according to the piece.

‘While the NSC official used his Gmail account, his interagency colleagues used government-issued accounts, headers from the email correspondence show,’ the Post reported.

The piece comes a week after Waltz took responsibility for one of his staffers accidentally adding The Atlantic editor-in-chief Jeffrey Goldberg to a sensitive Signal chat with other officials, including Vice President JD Vance.

NSC spokesperson Brian Hughes told Fox News on Tuesday that the Post report was an attempt ‘to distract the American people from President Trump’s successful national security agenda that’s protecting our nation.’

‘Let me reiterate, NSA Waltz received emails and calendar invites from legacy contacts on his personal email and cc’d government accounts for anything since January 20th to ensure compliance with records retention, and he has never sent classified material over his personal email account or any unsecured platform,’ Hughes said.

Hughes said that he could not verify the Post’s report about the senior NSC official because the journalist ‘refused to share any part of the document reported.’

‘Any correspondence containing classified material must only be sent through secure channels and all NSC staff are informed of this,’ the official said. ‘It is also made clear to NSC personnel that any non-government correspondence must be captured and retained for record compliance.’

Speaking to a room full of reporters last week, President Donald Trump said he believes Waltz is ‘doing his best,’ and did not fault him for the Signal leak.

‘I don’t think he should apologize,’ the president said. ‘I think he’s doing his best. It’s equipment and technology that’s not perfect.’

‘And, probably, he won’t be using it again, at least not in the very near future,’ Trump continued.


This post appeared first on FOX NEWS

Sen. Cory Booker, D-N.J., spoke out against President Donald Trump and Elon Musk on the Senate floor throughout the night after beginning his marathon speech at 7 p.m. Monday.

The senator was still speaking on the floor as of Tuesday afternoon, more than 18 hours after he had begun.

Over 24 hours later, at 7:20 p.m. on Tuesday, Booker had broken the record for the longest Senate floor speech.

Booker yielded to Sen. Chuck Schumer so he could ask the New Jersey Senator a question.

‘Do you know you have just broken the record?’ Schumer asked. ‘Do you know how proud this caucus is of you? Do you know how proud America is of you?’

Everyone in the chamber, besides the press, gave Booker a standing ovation, including those in the gallery and senate pages.

Sen. Tina Smith, D-Minn., was seen wiping a tear from her face, while Sen. Cynthia Lummis, R-Wyo., was also seen standing and applauding.

Booker received some support from other Senate Democrats, whom he allowed to speak at times during his hourslong show of opposition against the Trump administration.

Booker said toward the beginning of his speech that Trump, in 71 days, ‘has inflicted so much harm on Americans’ safety, financial stability, the core foundations of our democracy, and even our aspirations as a people for, from our highest offices, a sense of common decency.’

Sen. Cory Booker says he will not be taking up Musk on Cybertruck offer

The senator claimed that the Trump administration and congressional Republicans are targeting Medicaid and Medicare programs to fund tax cuts for billionaires and corporations.

He spent some of his time reading messages from people who wrote about various topics, including concerns about Medicare, Medicaid, and Social Security.

Trump has previously indicated that he will not ‘touch’ Americans’ Social Security, Medicare, or Medicaid benefits, but wants to weed out fraud.

Sen. Chris Murphy, D-Conn., who said he planned to join Booker ‘for the entirety of his speech,’ noted that he was ‘returning the favor’ as Booker joined him when he ‘launched a filibuster to demand action on gun violence nine years ago.’

Cory Booker blasts Trump during marathon speech

Murphy was among the Democrats who provided Booker with some relief by speaking at times to punctuate the marathon session.

In the social media video, Murphy described his colleague’s effort as ‘extraordinary.’

Booker said in a video before he began his demonstration that he plans to continue speaking as long as he is ‘physically able.’


This post appeared first on FOX NEWS

Pontax Lithium Project, James Bay, Canada

Cygnus Metals Limited (ASX: CY5, TSXV: CYG, OTCQB: CYGGF) is pleased to announce that it has negotiated a two-year extension to its two-stage earn-in with Stria Lithium Inc (‘Stria’) for the Pontax Lithium Project in James Bay, Quebec (‘Pontax’).

In July 2023, Cygnus announced that it had earned 51 per cent of Pontax under the first stage of the earn-in by spending C$4 million on the project and issuing 9,129,825 fully paid ordinary shares in Cygnus (‘Shares’) to Stria.

As a demonstration of the co-operation between Stria and Cygnus, the parties have now agreed that Cygnus has an additional 24 months to satisfy the second stage of the earn-in and earn an additional 19% interest in Pontax, bringing its total interest to 70%.

The extension means that Cygnus has until October 2027 to expend an additional C$2 million on exploration at the project and make a cash payment to Stria of C$3 million, enhancing the likelihood of successful exploration outcomes at Pontax.

As consideration for the extension and subject to TSXV approval, Cygnus will shortly issue 300,000 Shares to Stria utilising the Company’s available Listing Rule 7.1 capacity at a deemed price of A$0.105 per Share (based on the ASX closing price on 1 April 2025). These Shares will be subject to voluntary escrow for a period of 12 months from issue.

This announcement has been authorised for release by the Board of Directors of Cygnus.

David Southam
Executive Chairman
T: +61 8 6118 1627
E: info@cygnusmetals.com

About Cygnus Metals

Cygnus Metals Limited (ASX: CY5, TSXV: CYG, OTCQB: CYGGF) is a diversified critical minerals exploration and development company with projects in Quebec, Canada and Western Australia. The Company is dedicated to advancing its Chibougamau Copper-Gold Project in Quebec with an aggressive exploration program to drive resource growth and develop a hub-and-spoke operation model with its centralised processing facility. In addition, Cygnus has quality lithium assets with significant exploration upside in the world-class James Bay district in Quebec, and REE and base metal projects in Western Australia. The Cygnus team has a proven track record of turning exploration success into production enterprises and creating shareholder value.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

This post appeared first on investingnews.com

Launching Industry-Specific Solutions to Drive Subscriber Base in 2nd Quarter 2025

Syntheia Corp. (CSE: SYAI) (‘Syntheia’ or the ‘Company’) (Syntheia.ai), a leading provider of conversational AI solutions for inbound telephone call management is pleased to report subscriptions to our Assistant NLP have surpassed 13,000 meeting management’s expectations for phase one of our marketing strategy.

Phase one focused on a broad marketing effort targeting the global small-to-medium business (SMB) market segment. As previously reported, the majority of our subscribers come from regions where English is a second language. Today, management reaffirms its revised growth target of 100,000 subscribers by the end of 2025.

Syntheia has developed an industry-specific solution for the medical industry tailored to the needs of doctors’ offices and wellness clinics. This solution is designed to enhance patient interactions by facilitating inquiries, scheduling appointments, and providing responses based on patient needs detected in conversation. In consultation with industry professionals, AssistantNLP has been optimized around three core pillars:

Smart Answers  Industry-specific answers to common patient questions.

Intelligent Interactions  On-going conversational knowledge learning.

Answer Calls 24/7  Active around the clock – maximizing patient communications.

Furthermore, we are actively developing industry-specific solutions tailored to the needs of:

  • Law Firms
  • Investment Advisors and Financial Planners
  • Real Estate Offices
  • Mortgage Brokers
  • Restaurants

By aligning our platform’s capabilities with the unique demands of these industries, we aim to drive continued growth and reinforce our market position.

We continue to commercialize and grow the platform and this is where the power of Syntheia’s AI capabilities come into play for scalability, adoption, and marketability,‘ commented Paul Di Benedetto, Chief Technology Officer. ‘Our focus on system automations and artificial intelligence allows us to streamline our operations, drive down operational costs and maximize brand awareness and sales growth.

About Syntheia

Syntheia is an artificial intelligence technology company which is developing and commercializing proprietary algorithms to deliver human-like conversations. Our SaaS platform offers conversational AI solutions for both enterprise and small-medium business customers globally.

For further information, please contact:

Tony Di Benedetto
Chief Executive Officer
Tel: (844) 796-8434

Cautionary Statement

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release.

This news release contains certain ‘forward-looking information’ within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as ‘plan’, ‘expect’, ‘project’, ‘intend’, ‘believe’, ‘anticipate’, ‘estimate’, ‘may’, ‘will’, ‘would’, ‘potential’, ‘proposed’ and other similar words, or statements that certain events or conditions ‘may’ or ‘will’ occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Forward-looking statements in this news release include, but are not limited to the Company’s mission and business objectives, the Company’s efforts to grow brand awareness, customer base and sales and the development of new features for the Company’s services. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made.

Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. Please refer to the Company’s listing statement available on SEDAR+ for a list of risks and key factors that could cause actual results to differ materially from those projected in the forward‐looking information. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change unless required by law. The reader is cautioned not to place undue reliance on forward-looking information.

The securities of the Company have not been and will not be registered under the United States Securities Act of 1933, as amended and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/246930

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com

Did you know you can generate more than a 5% monthly yield by utilizing an options strategy? 

In this educational video, Tony Zhang walks you through an income-generating options strategy using the OptionsPlay Strategy Center on StockCharts.com.

Learn how to select the right stocks, identify strike prices and expiration dates, analyze various outcomes, and manage your trades.

Armed with this knowledge, you will never want to miss out on the opportunity to generate income from your portfolio. 

This video premiered on April 1, 2025.